Research programme: glucocorticoid-induced tumour necrosis factor receptor agonists - Apogenix

Drug Profile

Research programme: glucocorticoid-induced tumour necrosis factor receptor agonists - Apogenix

Alternative Names: GITR agonists - Apogenix; Glucocorticoid induced TNFR-related protein agonists - Apogenix; HERA GITR agonists; HERA GITR ligands; HERA-GITRL; Hexavalent GITR agonists - Apogenix; TNFRSF18 agonists - Apogenix

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apogenix
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Sep 2017 Preclinical trials in Head and neck cancer in Germany (unspecified route)
  • 13 Sep 2017 Preclinical trials in Non-small cell lung cancer in Germany (unspecified route)
  • 16 May 2017 Glucocorticoid-induced tumour necrosis factor receptor agonists are still available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top